Amitiza Dosage
For chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC), the recommended dose is 24 mcg twice daily; for irritable bowel syndrome with constipation (IBS-C) in women, use 8 mcg twice daily. 1
Adult Dosing by Indication
Chronic Idiopathic Constipation (CIC)
- Standard dose: 24 mcg twice daily with food and water 1
- This dose demonstrated significant improvement in spontaneous bowel movements (SBMs) per week compared to placebo (mean difference 1.98 SBMs) 2
- Treatment duration in trials was 4 weeks, though the FDA label does not specify a maximum duration 2
Opioid-Induced Constipation (OIC)
- Standard dose: 24 mcg twice daily with food and water 1
- Approved for adult patients with chronic, non-cancer pain 1
- Critical limitation: Effectiveness has NOT been established in patients taking diphenylheptane opioids (e.g., methadone) 1. Pooled analysis confirmed lubiprostone is effective only for non-methadone opioids 3
- Patients requiring frequent (e.g., weekly) opioid dose escalation should not use this medication 1
Irritable Bowel Syndrome with Constipation (IBS-C)
- Standard dose: 8 mcg twice daily with food and water 1
- Approved only for women ≥18 years old 1
- The lower dose (8 mcg vs 24 mcg) reduces nausea risk while maintaining efficacy for IBS-C 2
Dosage Adjustments
Hepatic Impairment
- Moderate to severe hepatic insufficiency: Reduce dose to 8 mcg twice daily 2
- This adjustment is necessary because systemic absorption, though negligible in healthy individuals, may be affected by liver dysfunction 2
Renal Impairment
- No specific dosage adjustment provided in FDA labeling 1
- Long-term studies showed no clinically meaningful effects on electrolytes, BUN, or creatinine 4
Administration Instructions
Key administration points to minimize adverse effects:
- Swallow capsules whole—do not break apart or chew 1
- Take with food and water to reduce nausea risk 2, 1
- Nausea is dose-dependent and significantly reduced when taken with meals 2
Pediatric Dosing
Safety and effectiveness have NOT been established in pediatric patients for IBS-C, pediatric functional constipation, or OIC 1. While one open-label study evaluated weight-based dosing (12 mcg once daily, 12 mcg twice daily, or 24 mcg twice daily) in children with functional constipation 5, this is not FDA-approved and should not be used in routine practice.
Clinical Context and Guideline Positioning
The 2019 AGA guideline for OIC makes no recommendation for lubiprostone due to an evidence gap 6. However, the 2023 AGA-ACG guideline for CIC conditionally suggests lubiprostone for patients who do not respond to over-the-counter agents, though the certainty of evidence is low 2.
For OIC specifically, the AGA strongly recommends PAMORAs (naldemedine, naloxegol) as first-line therapy after laxative failure, rather than lubiprostone 6. This reflects the stronger evidence base for PAMORAs in this population.
Common Pitfalls
- Do not use in patients with known or suspected mechanical GI obstruction (absolute contraindication) 1
- Avoid in patients with severe diarrhea 1
- Nausea occurs in approximately 29% of CIC patients and 11% of OIC patients; taking with food significantly reduces this 2, 1
- Diarrhea leading to discontinuation occurs in approximately 2% of patients 1
- Assess periodically whether continued therapy is needed 1